Literature DB >> 17904401

Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults.

Swapnil N Rajpathak1, Aileen P McGinn, Howard D Strickler, Thomas E Rohan, Michael Pollak, Anne R Cappola, Lewis Kuller, XiaoNan Xue, Anne B Newman, Elsa S Strotmeyer, Bruce M Psaty, Robert C Kaplan.   

Abstract

Increasing evidence suggests that the insulin-like growth factor (IGF)-axis may play a role in glucose metabolism and may also be associated with systemic inflammation. The aim of this study was to evaluate the association of insulin-like growth factor-1 (IGF-I) and its binding proteins, IGFBP-1 and IGFBP-3, with glucose intolerance and inflammation among older adults. We conducted a cross-sectional analysis in a in a random subsample (n=922) of the Cardiovascular Health Study (CHS), a prospective cohort of men and women > or = 65 years. Mean IGFBP-1 levels were significantly lower in older adults with impaired glucose tolerance (IGT), impaired fasting glucose (IFG) and diabetes compared to those with normal fasting and post-load glucose. High IGFBP-1 was associated with a reduced prevalence of IGT and IFG; the multivariable OR between extreme quartiles of IGFBP-1 was 0.60 (95% CI: 0.37, 0.95; p-trend: 0.03) for IGT and 0.41 (95% CI: 0.26, 0.64; p-trend: <0.01) for IFG. We did not find any significant association between IGF-I and glucose intolerance in this study and the association for IGFBP-3 was less clear. However, low levels of IGF-I and IGFBP-3 were associated with increased levels of markers of inflammation including C-reactive protein and interleukin-6 levels. We conclude that among adults > or = 65 years, low IGFBP-1 levels are associated with increased prevalence of glucose intolerance. We did not confirm prior associations of low IGF-I with glucose intolerance in this cohort of older individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904401      PMCID: PMC2492581          DOI: 10.1016/j.ghir.2007.08.004

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  41 in total

1.  A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction.

Authors:  N Vaessen; P Heutink; J A Janssen; J C Witteman; L Testers; A Hofman; S W Lamberts; B A Oostra; H A Pols; C M van Duijn
Journal:  Diabetes       Date:  2001-03       Impact factor: 9.461

Review 2.  Serum levels of insulin-like growth factor I and its binding proteins in health and disease.

Authors:  Anders Juul
Journal:  Growth Horm IGF Res       Date:  2003-08       Impact factor: 2.372

3.  Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes.

Authors:  J Frystyk; C Skjaerbaek; E Vestbo; S Fisker; H Orskov
Journal:  Diabetes Metab Res Rev       Date:  1999 Sep-Oct       Impact factor: 4.876

4.  No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance.

Authors:  W Ricart; J M Fernández-Real
Journal:  Obes Res       Date:  2001-10

5.  Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke.

Authors:  Robert C Kaplan; Aileen P McGinn; Michael N Pollak; Lewis H Kuller; Howard D Strickler; Tom E Rohan; Anne R Cappola; XiaoNan Xue; Bruce M Psaty
Journal:  J Clin Endocrinol Metab       Date:  2007-01-30       Impact factor: 5.958

6.  Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study.

Authors:  Manjinder S Sandhu; Adrian H Heald; J Martin Gibson; J Kennedy Cruickshank; David B Dunger; Nicholas J Wareham
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

7.  Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity.

Authors:  S Yakar; J L Liu; A M Fernandez; Y Wu; A V Schally; J Frystyk; S D Chernausek; W Mejia; D Le Roith
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

8.  Metabolic, anthropometric, and nutritional factors as predictors of circulating insulin-like growth factor binding protein-1 levels in middle-aged and elderly men.

Authors:  Katarina Wolk; Susanna C Larsson; Bengt Vessby; Alicja Wolk; Kerstin Brismar
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

9.  Free and total insulin-like growth factor (IGF)-I levels decline during fasting: relationships with insulin and IGF-binding protein-1.

Authors:  Lorraine E L Katz; Diva D DeLeón; Hui Zhao; Abbas F Jawad
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

10.  Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.

Authors:  Anders Juul; Thomas Scheike; Michael Davidsen; Jesper Gyllenborg; Torben Jørgensen
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

View more
  29 in total

Review 1.  Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

Authors:  David R Clemmons
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

Review 2.  The IGF-I regulatory system and its impact on skeletal and energy homeostasis.

Authors:  Masanobu Kawai; Clifford J Rosen
Journal:  J Cell Biochem       Date:  2010-09-01       Impact factor: 4.429

3.  Comparison of Intermittent Fasting Versus Caloric Restriction in Obese Subjects: A Two Year Follow-Up.

Authors:  F B Aksungar; M Sarıkaya; A Coskun; M Serteser; I Unsal
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

4.  The Association Between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study.

Authors:  Chino S Aneke-Nash; Xiaonan Xue; Qibin Qi; Mary L Biggs; Anne Cappola; Lewis Kuller; Michael Pollak; Bruce M Psaty; David Siscovick; Kenneth Mukamal; Howard D Strickler; Robert C Kaplan
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

5.  Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.

Authors:  Charles S Fuchs; Richard M Goldberg; Daniel J Sargent; Jeffrey A Meyerhardt; Brian M Wolpin; Erin M Green; Henry C Pitot; Michael Pollak
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

Review 6.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

7.  RTEF-1 attenuates blood glucose levels by regulating insulin-like growth factor binding protein-1 in the endothelium.

Authors:  Angela F Messmer-Blust; Melissa J Philbrick; Shuzhen Guo; Jiaping Wu; Ping He; Shaodong Guo; Jian Li
Journal:  Circ Res       Date:  2012-07-25       Impact factor: 17.367

8.  Association between serum IGF-1 and diabetes among U.S. adults.

Authors:  Srinivas Teppala; Anoop Shankar
Journal:  Diabetes Care       Date:  2010-07-16       Impact factor: 19.112

9.  Serum IGF-I and C-reactive protein in healthy black and white young men: the CARDIA male hormone study.

Authors:  Laura A Colangelo; Brian Chiu; Peter Kopp; Kiang Liu; Susan M Gapstur
Journal:  Growth Horm IGF Res       Date:  2009-01-12       Impact factor: 2.372

10.  Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men.

Authors:  M S Lewitt; A Hilding; C-G Ostenson; S Efendic; K Brismar; K Hall
Journal:  Diabetologia       Date:  2008-05-22       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.